Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients

American Journal of Gastroenterology

Volumn 101, Issue 9, 2006, Pages 2044-2050

  Ter Borg, Pieter C J ^a   Schalm, Solko W ^a   Hansen, Bettina E ^a   Van Buuren, Henk R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LIVER GRAFT; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 33748375153     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00699.x     Document Type: Article

References (31)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996;335:1570-80.
2. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
3. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis Cochrane Database Syst Rev 2002:CD000551. J Hepatol 1999;30:83A.
4. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999;354:1053-60.
5. Flather MD, Farkouh ME, Pogue JM, et al. Strengths and limitations of meta-analysis: Larger studies may be more reliable. Control Clin Trials 1997;18:568-79; discussion 661-6.
6. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000;46:121-6.
7. Poupon RE, Bonnand AM, Chretien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999;29:1668-71.
8. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989;10:1-7.
9. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
10. Chan CW, Gunsar F, Feudjo M, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: A follow-up to 12 years. Aliment Pharmacol Ther 2005;21:217-26.
11. Christensen E, Altman DG, Neuberger J, et al. Updating prognosis in primary biliary cirrhosis using a time dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 1993;105:1865-76.
12. Krzeski P, Zych W, Kraszewska E, et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999;30:865-9.
13. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002;123:1044-51.
14. Murtaugh PA, Dickson ER, Van Dam GM, et al. Primary biliary cirrhosis: Prediction of short-term survival based on repeated patient visits. Hepatology 1994;20:126-34.
15. Roll J, Boyer JL, Barry D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7.
16. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89:1084-91.
17. van Hoogstraten HJF, Hansen BE, van Buuren HR, et al. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol 1999;31:256-62.
18. Taal BG, Schalm SW, ten Kate FW, et al. Clinical diagnosis of primary biliary cirrhosis: A classification based on major and minor criteria. Hepatogastroenterology 1983;30:178-82.
19. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-12.
20. Tersmette AC, Offerhaus GJ, Giardiello FM, et al. Long-term prognosis after partial gastrectomy for benign conditions. Survival and smoking-related death of 2633 Amsterdam postgastrectomy patients followed up since surgery between 1931 and 1960. Gastroenterology 1991;101:148-53.
21. Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-54.
22. Koulentaki M, Moscandrea J, Dimoulios P, et al. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004;49:1190-5.
23. Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9.
24. Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: Treat early to slow progression. J Hepatol 2003;39:112-4.
25. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989;10:846-50.
26. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a U. S. community (in process citation). Gastroenterology 2000;119:1631-6.
27. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
28. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:707-13.
29. Mitchison HC, Lucey MR, Kelly PJ, et al. Symptom development and prognosis in primary biliary cirrhosis: A study in two centers. Gastroenterology 1990;99:778-84.
30. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-6.
31. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.